Merck Q1 sales up 9% to $15.8B; raises FY2024 sales and EPS guidance

Merck & Co., Inc.

2024-Q1 EPS reported $1.87 revenue$15,775,000,000

GAAP EPS $1.87 (+68% YoY); Non-GAAP EPS $2.07 (+48% YoY). Sales $15.775B (+9%, +12% ex-FX).
Keytruda sales grew 20% to $6.9B; Gardasil sales up 14% to $2.2B on strong China demand.
Full-year 2024 sales outlook raised to $63.1-$64.3B; Non-GAAP EPS outlook raised to $8.53-$8.65.
Received FDA approval for WINREVAIR (PAH); closed Harpoon acquisition with $656M charge.
Proposed acquisition of Elanco's aqua business to broaden animal health portfolio.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Merck & Co., Inc. reported first quarter of 2024 results: revenue $15,775, net income 4,762, EPS GAAP EPS 1.87; Non-GAAP EPS that excludes certain items 2* 2.07. Guidance raised.

Period: first quarter of 2024
Revenue: $15,775
Net income: 4,762
EPS: GAAP EPS 1.87; Non-GAAP EPS that excludes certain items 2* 2.07
Guidance: raised
Result: reported results

Exact text from the filing

Financial Summary First Quarter $ in millions, except EPS amounts 2024 2023 Change Change Ex- Exchange Sales $ 15,775 $ 14,487 9 % 12 % GAAP net income 1 4,762 2,821 69 % 76 % Non-GAAP net income that excludes certain items 1,2* 5,279 3,564 48 % 54 % GAAP EPS 1.87 1.11 68 % 76 % Non-GAAP EPS that excludes certain items 2* 2.07 1.40 48 % 54 %

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Merck & Co., Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-051517

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.